Clinical Trials Logo

Esophageal Cancer clinical trials

View clinical trials related to Esophageal Cancer.

Filter by:

NCT ID: NCT00573131 Terminated - Esophageal Cancer Clinical Trials

Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Start date: January 2008
Phase: Phase 2
Study type: Interventional

OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel. The protocol is directed towards evaluating the efficacy and safety of paclitaxel delivered as a local, intralesional treatment when used in combination with chemotherapy (cisplatin and 5-FU) and radiation therapy before surgery.

NCT ID: NCT00566800 Recruiting - Esophageal Cancer Clinical Trials

Erlotinib in Treating Patients With Barrett Esophagus

Start date: July 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with Barrett esophagus.

NCT ID: NCT00561275 Completed - Esophageal Cancer Clinical Trials

Safety Study of Multiple Peptide Vaccine to Esophageal Cancer

Start date: October 2007
Phase: Phase 1
Study type: Interventional

This is a phase 1 study of multiple peptide vaccine therapy and GM-CSF in treating patients with esophageal cancer.

NCT ID: NCT00551759 Terminated - Esophageal Cancer Clinical Trials

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Start date: October 2, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving docetaxel and cetuximab after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving chemotherapy and radiation therapy together with cetuximab followed by surgery, docetaxel and cetuximab works in treating patients with esophageal cancer or gastroesophageal junction cancer.

NCT ID: NCT00544362 Completed - Esophageal Cancer Clinical Trials

Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery

Start date: July 2007
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving fluorouracil and cisplatin together with cetuximab and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of fluorouracil and cisplatin when given together with cetuximab and radiation therapy in treating patients with esophageal cancer that can be removed by surgery.

NCT ID: NCT00539617 Terminated - Esophageal Cancer Clinical Trials

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Start date: October 5, 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.

NCT ID: NCT00537121 Completed - Gastric Cancer Clinical Trials

Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer

Start date: November 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with irinotecan, fluorouracil, and leucovorin in treating patients with advanced upper gastrointestinal cancer.

NCT ID: NCT00534001 Completed - Lung Cancer Clinical Trials

Bupropion in Helping Adults Stop Smoking

Start date: January 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking. PURPOSE: This randomized phase II trial is studying how well bupropion works in helping adults stop smoking.

NCT ID: NCT00533884 Completed - Lung Cancer Clinical Trials

Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic

Start date: October 2007
Phase: N/A
Study type: Observational

RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease. PURPOSE: This clinical trial is studying neurocognitive functioning in patients with newly diagnosed upper aerodigestive tract cancers receiving treatment at Henry-Joyce Cancer Clinic.

NCT ID: NCT00531180 Completed - Lung Cancer Clinical Trials

4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies

Start date: August 21, 2007
Phase: Phase 2
Study type: Interventional

Objectives: Primary Objective: 1. To determine the correlation between 4-dimensional computed tomography (4D CT) derived ventilation and single photon emission tomography (SPECT) aerosol Tc-99m determined ventilation. Secondary Objective: 1. To evaluate the reproducibility of the 4D CT derived ventilation and to obtain an estimate of the variance in a single setting. 2. To assess the correlation between hypoperfused and hypoventilated pulmonary regions in patients with thoracic malignancies. 3. To investigate the effect of continuous positive airway pressure (CPAP) on ventilation and tumor motion.